A common analgesic enhances the anti-tumour activity of 5-aza-2'-deoxycytidine through induction of oxidative stress
Gleneadie, H. J.; Baker, A. H.; Batis, N.; Bryant, J.; Jiang, Y.; Clokie, S. J.; Mehanna, H.; Garcia, P.; Gendoo, D. M.; Roberts, S.; Molinolo, A.; Gutkind, S.; Scheven, B. A.; Cooper, P. R.; Khanim, F.; Wiench, M.
Show abstract
The DNA demethylating agent 5-aza-2-deoxycytidine (DAC, decitabine) has anti-cancer therapeutic potential, but its clinical efficacy is hindered by DNA damage-related side effects. Here we describe how paracetamol augments the effects of DAC on cancer cell proliferation and differentiation, without enhancing DNA damage. Firstly, DAC specifically upregulates cyclooxygenase-2-prostaglandin E2 pathway, inadvertently increasing cancer cell survival, while the addition of paracetamol offsets this effect. Secondly, combined treatment leads to glutathione depletion and ROS accumulation with oxidative stress further enhanced by DAC suppressing anti-oxidant and thioredoxin responses. The benefits of combined treatment are demonstrated here in head and neck squamous cell carcinoma (HNSCC) and acute myeloid leukaemia cell lines, further corroborated in a HNSCC xenograft mouse model and through mining of publicly available DAC and paracetamol responses. In summary, the addition of paracetamol could allow for DAC dose reduction, widening its clinical usability and providing a strong rationale for consideration in cancer therapy.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 96%
- Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting 95%
- A novel role for the tumor suppressor gene ITF2 in lung tumorigenesis and chemotherapy response 95%
Similar papers in this journal
- Clinical positioning of the IAP antagonist tolinapant (ASTX660) in colorectal cancer 95%
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 95%
- The methyltransferases METTL7A and METTL7B confer resistance to thiol-based histone deacetylase inhibitors 95%
Similar papers in this journal
- PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer 95%
- T2R bitter taste receptors regulate apoptosis and may be associated with survival in head and neck squamous cell carcinoma 95%
- TPX2 expression promotes sensitivity to dasatinib in breast cancer by activating the YAP transcriptional signaling. 95%
Similar papers in this journal
- NRF2 upregulation by CDDO-Me protects AC16 human cardiomyocytes against doxorubicin-induced toxicity. 96%
- Zebrafish Drug Screening Identifies Erlotinib as an Inhibitor of Wnt/β-Catenin Signaling and Self-Renewal in T-cell Acute Lymphoblastic Leukemia 95%
- Novel assays monitoring direct glucocorticoid receptor protein activity exhibit high predictive power for ligand activity on endogenous gene targets 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.